Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2290500 | 1.00 | CA12 (0.42) | CA12CA9CA1CA2TSHR | |
| SCHEMBL11548379 | 1.00 | CA12 (0.42) | CA12CA9CA1CA2TSHR | |
| SCHEMBL11746006 | 1.00 | CA12 (0.42) | CA12CA9CA1CA2TSHR | |
| SCHEMBL11548381 | 1.00 | CA12 (0.42) | CA12CA9CA1CA2TSHR | |
| SCHEMBL19464089 | 0.91 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL6561491 | 0.89 | CA12 (0.37) | CA12CA9CA1CA2TSHR | |
| SCHEMBL8490943 | 0.89 | CA12 (0.43) | CA12CA9CA1CA2TSHR | |
| SCHEMBL11835924 | 0.87 | CA12 (0.40) | CA12CA9CA1CA2TSHR | |
| SCHEMBL11835919 | 0.87 | CA12 (0.40) | CA12CA9CA1CA2TSHR | |
| SCHEMBL9600313 | 0.87 | CA12 (0.40) | CA12CA9CA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012063126-A2 | IMPROVED PROCESSES FOR PREPARING PURE (3AR,4S,6R,6AS)-6-AMINO-2,2-DIMETHYLTETRAHDRO-3AH-CYCLOPENTA[D] [1,3]-DIOXOL-4-OL AND ITS KEY STARTING MATERIAL | ACTAVIS GROUP PTC EHF (IS) | 2012-05-18 | — | — | WO | claimed |
| EP-1428888-B1 | Method for the production of (1S,4R)-(-)-4-Hydroxycyclopent-2-enyl esters | ARCHIMICA GMBH (DE) | 2008-10-22 | — | — | EP | claimed |
| US-20040126855-A1 | Method for the production of (1S, 4R)-(-)-4-hydroxy cyclopent-2-enyl esters | CLARIANT GMBH | 2004-07-01 | — | — | US | claimed |
| EP-1428888-A1 | Method for the production of (1S,4R)-(-)-4-Hydroxycyclopent-2-enyl esters | Clariant GmbH (DE) | 2004-06-16 | — | — | EP | claimed |
| EP-0249859-A2 | Process for the preparation of (1R,4S)-4-hydroxy-2-cyclopentenyl esters | BAYER AG (DE) | 1987-12-23 | — | — | EP | claimed |
| EP-0167759-A1 | Process for the preparation of (1S,4R)-4-hydroxy-2-cyclopentenyl esters | BAYER AG (DE) | 1986-01-15 | — | — | EP | claimed |
| JP-51115460-A | — | — | None | — | — | JP | disclosed |
| EP-4015005-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3682905-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| US-20210299278-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210179665-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | PARABILIS MEDICINES, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-2922859-B1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIV CORK (IE) | 2021-05-05 | — | — | EP | disclosed |
| WO-1993005146-A1 | MOLECULES WITH ANTIBODY COMBINING SITES THAT INDUCE ASYMMETRY | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-03-18 | — | — | WO | disclosed |
| US-5032523-A | Preparation of optically active esters | LION CORPORATION (JP) | 1991-07-16 | — | — | US | disclosed |
| US-4873360-A | Process for the preparation of cyclopentanoids and novel intermediates produced thereby | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0249859-A2 | Process for the preparation of (1R,4S)-4-hydroxy-2-cyclopentenyl esters | BAYER AG (DE) | 1987-12-23 | — | — | EP | disclosed |
| US-4008125-A | New cyclopentene-diols and new acyl esters thereof and process for their preparation | TEIJIN LIMITED (JA) | 1977-02-15 | — | — | US | disclosed |
| US-4001308-A | REACTION OF DIBROMO COMPOUND WITH METAL SALT OF ACETIC ACID | TEIJIN LIMITED (JA) | 1977-01-04 | — | — | US | disclosed |
| JP-S51115460-A | METHOD FOR PREPARING 2-OXABICYCLO-(3.3.0)-OCT-B-ENE-3-ONE | TAKANO SEIICHI | 1976-10-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | CA12 3297/4885CA9 2016/4885CA1 4691/4885 |
| US-20210299278-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLN, POLM | CA12 4387/4885CA9 4572/4885CA1 4864/4885 |
| US-20210179665-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | IAPP, VIP, NGLY1 | CA12 1171/4885CA9 2094/4885CA1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.